Structurally-engineered fatty acid 1024 (SEFA-1024) as treatment for non-alcoholic fatty liver disease
Jordan Secor, *Bennet Cho, *Amy Pan, Lumeng Yu, Victoria Ko, Mark Puder
Boston Children's Hospital, Boston, MA
Objective: Assess the efficacy of a novel drug, structurally-engineered fatty acid 1024 (SEFA-1024), in treating high fat diet (HFD)-induced obesity, steatohepatitis, and insulin resistance in a murine model.
Therapies are needed to treat the 24% of Americans with non-alcoholic fatty liver disease (NAFLD) and mitigate the shortage of liver transplant donors relative to recipients.
Design: Randomized, controlled trial in mice
Participants: C57BL/6 mice
Interventions: C57BL/6 mice were fed chow (10% kcal from fat) or HFD (60% kcal from fat) ad lib for 15 weeks.Subsequently, the HFD group were treated with SEFA-1024 or MCT as a vehicle control. After 5 weeks of treatment, all mice underwent oral glucose tolerance testing (GTT). One week later, body and organ masses, serum AST and ALT, and liver histology were analyzed.
Main Outcome Measures: Change in body mass, liver steatosis, hyperglycemia and hyperinsulinemia on GTT, and liver enzymes
SEFA-1024 treats HFD-induced obesity, steatohepatitis, and insulin resistance. SEFA-1024 reversed obesity caused by HFD (A). On GTT, SEFA-1024 inhibited HFD-induced hyperglycemia (B) and hyperinsulinemia (C). Liver H&E staining (D-F) demonstrated HFD-mediated hepatic steatosis (E, arrows) which was treated by SEFA-1024 (F). Serum AST and ALT were elevated by HFD but not when treated with SEFA-1024 (G&H).
Conclusions: SEFA-1024 reduces HFD-induced obesity, hepatic steatosis, inflammation, hyperglycemia, and hyperinsulinemia in a murine model of chronic, diet-induced liver injury. SEFA-1024 demonstrates the potential to mitigate the deleterious effects of metabolic syndrome in obese patients which could reduce the prevalence of NAFLD and need for liver transplantation.
Back to 2020 Abstracts